1-1-2009

Osteoarthritis associated with estrogen deficiency.

Jorge A Roman-Blas  
*Bone and Joint Research Unit, Service of Rheumatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid 28040, Spain, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia 19107, USA, jorge.roman-blas@jefferson.edu*

Santos Castañeda  
*Department of Rheumatology, Hospital de la Princesa, Universidad Autónoma, Madrid 28005, Spain*

Raquel Largo  
*Bone and Joint Research Unit, Service of Rheumatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid 28040, Spain, rlargo@fjd.es*

Gabriel Herrero-Beaumont  
*Bone and Joint Research Unit, Service of Rheumatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid 28040, Spain, gherrero@fjd.es*

Let us know how access to this document benefits you

Recommended Citation  
Roman-Blas, Jorge A; Castañeda, Santos; Largo, Raquel; and Herrero-Beaumont, Gabriel, "Osteoarthritis associated with estrogen deficiency." (2009). *Jefferson Institute of Molecular Medicine Papers and Presentations*. Paper 1.  
https://jdc.jefferson.edu/jimmp/1

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Jefferson Institute of Molecular Medicine Papers and Presentations by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Review

Osteoarthritis associated with estrogen deficiency

Jorge A Roman-Blas1,2, Santos Castañeda3, Raquel Largo1 and Gabriel Herrero-Beaumont1

1Bone and Joint Research Unit, Service of Rheumatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid 28040, Spain
2Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia 19107, USA
3Department of Rheumatology, Hospital de la Princesa, Universidad Autónoma, Madrid 28005, Spain

Corresponding author: Gabriel Herrero-Beaumont, gherrero@fjd.es

Published: 21 September 2009
This article is online at http://arthritis-research.com/content/11/5/241
© 2009 BioMed Central Ltd

Abstract

Osteoarthritis (OA) affects all articlar tissues and finally leads to joint failure. Although articlar tissues have long been considered unresponsive to estrogens or their deficiency, there is now increasing evidence that estrogens influence the activity of joint tissues through complex molecular pathways that act at multiple levels. Indeed, we are only just beginning to understand the effects of estrogen deficiency on articlar tissues during OA development and progression, as well as on the association between OA and osteoporosis. Estrogen replacement therapy and current selective estrogen receptor modulators have mixed effectiveness in preserving and/or restoring joint tissue in OA. Thus, a better understanding of how estrogen acts on joints and other tissues in OA will aid the development of specific and safe estrogen ligands as novel therapeutic agents targeting the OA joint as a whole organ.

Introduction

Osteoarthritis (OA) is a very common chronic disease that affects all joint tissues, causing progressive irreversible damage and, finally, the failure of the joint as an organ [1]. Characteristic pathological changes in OA not only include joint cartilage degeneration but also subchondral bone thickening, osteophyte formation and synovial inflammation, all of which are associated with capsule laxitude and decreased muscle strength [1,2]. The pathological changes that occur in OA are the result of the action of biomechanical forces coupled with multiple autocrine, paracrine and endocrine cellular events that lead to a breakdown of the normal balance in tissue turnover within the joint [3,4].

Among the multiple physiopathological mechanisms involved in OA, those related to sex hormone control have been attracting much attention, in particular those involving estrogens [5]. In contrast to other tissues such as the endometrium, breast, brain and non-joint bone, it was traditionally thought that joint tissues were non-responsive to estrogens and estrogen deficit. However, interest in estrogens was stimulated by the large proportion of postmenopausal women with OA and the complexity of their role in this disease. Indeed, considerable efforts have been made to understand the potential role of estrogens in the biology of joint tissues, as well as in the development and progression of OA, which has led to a better understanding of the effects of estrogen on joint tissues and on cartilage in particular [5-7].

There is increasing evidence that estrogens fulfill a relevant role in maintaining the homeostasis of articlar tissues and, hence, of the joint itself. The dramatic rise in OA prevalence among postmenopausal women [8,9], which is associated with the presence of estrogen receptors (ERs) in joint tissues [10-14], suggests a link between OA and loss of ovarian function. This association indicates a potential protective role for estrogens against the development of OA. Indeed, recent in vitro, in vivo, genetic and clinical studies have shed further light on these issues.

This review is based on a literature search of peer-reviewed articles written in English in the Medline and PubMed databases from 1952 to April 2009 carried out using the keywords estrogen, menopause, estrogen replacement therapy (ERT) and selective estrogen receptor modulators (SERMs) alone or in various combinations with joint, cartilage, subchondral bone, synovium, ligaments, muscle, tendons, OA and osteoporosis (OP). Accordingly, it addresses the effect of estrogen deficit on all joint tissues and the dual action of

ACL = anterior cruciate ligament; AF = activation function; AP = activator protein; BMD = bone mineral density; E2 = 17β-estradiol; ER = estrogen receptor; ERE = estrogen response element; ERK = extracellular signal regulated kinase; ERT = estrogen replacement therapy; IGFBP = IGF-binding protein; IL = interleukin; MAP = mitogen activated protein; MMP = matrix metalloproteinase; NCoR = nuclear receptor co-repressor; NF = nuclear factor; OA = osteoarthritis; OB = osteoblast; OP = osteoporosis; OVX = ovariectomized; PI3 = phosphatidylinositol-3; PKC = protein kinase C; SERM = selective estrogen receptor modulators; SMAD = mothers against decapentaplegic; SMRT = silencing mediator for the retinoic acid and thyroid hormone receptor; Sp = specificity protein; TGF = transforming growth factor; TNF = tumor necrosis factor.
estrogen deficit on the association of OP and cartilage damage. In addition, we emphasize the relevance of these effects in the onset and/or progression of OA as well as summarizing our current knowledge on how estrogen regulates the metabolism of joint tissues. Finally, we examine the effects of ERT and current SERMs in OA, as well as the development of new specific estrogen ligands as potential therapeutic strategies to treat this disease.

The effects of estrogen deficiency on components of the osteoarthritis joint

Different studies have provided compelling information on the relevant effects of estrogen deficiency on joint components in cell culture, animal models or humans. Although much of the attention has focused on the effects of estrogen on articular cartilage, estrogen deficiency also affects other joint tissues during the course of OA, such as the periarticular bone, synovial lining, muscles, ligaments and the capsule (Figure 1).

**In vitro studies**

Several experimental studies have shown that estrogens are implicated in the regulation of cartilage metabolism. Indeed, 17β-estradiol (E2) enhances glycosaminoglycan synthesis in cultures of rabbit joint chondrocytes through the up-regulation of the uridine diphosphate glucose dehydrogenase gene [15]. Furthermore, estrogen (1 to 100 nM) significantly impairs the release of C-telopeptide of type II collagen from TNF-α and oncostatin M-stimulated bovine cartilage explants ex vivo in a dose-dependent manner [16]. In addition, E2 inhibits cyclooxygenase-2 mRNA expression in bovine articular chondrocytes and protects them from reactive oxygen species-induced damage [17,18]. However, the effects of high doses of estrogen on chondrocytes are contradictory. High concentrations of E2 lead to deleterious effects such as suppression of DNA synthesis in human chondrocytes [19], as well as the inhibition of proteoglycan synthesis and cell division in both bovine chondrocytes and cartilage explants [20,21]. A significant difference in ER affinity for its ligand as a function of age was observed. Human chondrocytes from early pubertal individuals display a maximal response to estrogens, while chondrocytes from neonatal children do not respond at all [22]. Similarly, ERs from pubertal rabbit chondrocytes exhibit higher affinity for estrogens than prepubertal chondrocytes [23]. Thus, estrogen dose and donor age are the main factors that influence chondrocyte response to estrogen.

These and many other relevant findings in vitro (discussed below) clearly show that estrogen influences the activity of all joint tissues through complex molecular mechanisms acting at multiple levels.

**In vivo studies**

The effects of estrogen on joint tissues have primarily been studied in ovariectomized (OVX) animal models. Despite these studies, the influence of estrogen deficiency on cartilage remains unclear, even though there is significant evidence of the detrimental effect of estrogen loss in mature female animals [7]. An increase in cartilage turnover and surface erosion was observed in OVX Sprague-Dawley rats [24], as well as in cynomolgus macaques subjected to bilateral OVX [25]. Significantly, intact females had less severe OA than OVX females and although intact male mice showed more severe OA than intact females, orchiectomized mice develop less OA than intact males [26]. By contrast, such associations could not be shown in other earlier studies [7]. Relevant changes have also been described in the subchondral bone of OVX animals. Indeed, OVX cynomolgus monkeys have higher indices of bone turnover in
subchondral bone compared to epiphyseal/metaphyseal cancellous bone of the proximal tibia [27]. Moreover, the marginal osteophyte area is positively correlated with subchondral bone thickness in the medial tibial plateau of these animals [28]. Significantly, subchondral bone remodeling has also been described in conjunction with changes in joint cartilage in a guinea pig model of spontaneous OA [29]. We found that rabbit subchondral bone has mixed densitometric characteristics with a marked predominance of cortical bone [30]. In fact, subchondral knee bone mineral density (BMD) is significantly correlated with the BMD of the spine, and trabecular and cortical knee bone in healthy, OA, OP and OP/OA rabbits [31].

Our rabbit model is a valuable tool to study OP because rabbits have much faster bone turnover than rodents or primates, and in contrast to rodents, they reach skeletal maturity soon after their sexual development is complete [32]. Moreover, since OVX itself only causes mild osteopenia, which may be insufficient to provoke OP in these animals, moderate doses of methylprednisolone were administered to ensure OP development [33]. We evaluated whether estrogen deficiency alone can induce OA alterations in healthy cartilage or, by contrast, whether OP subchondral bone is the origin of the cartilage changes in these animals. Estrogen deficiency leads to mild OA changes 22 weeks after isolated OVX in healthy articular cartilage, while OVX and methylprednisolone-induced OP play an additional role in these osteoarthritic changes (Figure 2). Thus, estrogen deprivation might produce a dual effect: a main direct action upon joint cartilage and a minor indirect effect on subchondral bone.

The influence of estrogen on the remaining joint tissues has not been studied directly in OA animal models. However, the involvement of these tissues in OA and the changes produced by estrogen in related animal models suggest a potential role of estrogen in OA changes. Indeed, the remodeling of the cruciate ligament is thought to occur early during knee OA in guinea pigs [29] and the potential role of endogenous estrogens in the disproportionate number of anterior cruciate ligament (ACL) injuries seen in female athletes has been studied in different animal models, although to date with negative results [34]. Besides, significant attenuation of histochemical and biochemical indices of muscle damage and inflammatory response were found in female rats after downhill running when compared with their male counterparts. Such an effect may possibly be explained by the higher circulating estrogen levels in these rats [35]. In addition, estrogen deficiency following OVX is often accompanied by an increase in fat mass, which in turn leads to increased adipokine levels, the role of which in OA is also now being investigated.

**Human studies**

Associations between polymorphisms in the human ERα gene (ESR1) and OA have been studied in different populations with mixed results. Haplotypes of the Pvull and Xbal polymorphisms in the ERα gene have been associated with an increased prevalence of clinical and radiographic knee OA [36-38]. In addition, the exon 8 G/A BtgI polymorphism was also associated with knee OA in Asian populations [38]. However, other studies showed either no or only a modest inverse relationship between ERα gene polymorphisms and OA in Caucasian populations [39,40].

Numerous clinical studies have also shown that OA is related to estrogen levels [8,9,41-47]. Thus, the prevalence of OA is greater in women than men and a clear increase in OA prevalence is associated with the peak age of menopause [8,9,41]. Indeed, a nationwide population survey showed that radiographic generalized OA is three times more common in women aged 45 to 64 years compared to their male counterparts [8], and a hospital-based study found a high female to male ratio of 10:1 for OA, with a peak at 50 years of age [42]. In addition, 64% of females with knee OA suffered the onset of symptoms either perimenopausally or within 5 years of natural menopause or hysterectomy. In fact, the onset of symptoms of knee OA occurred before 50 years of age in 58% of females as opposed to only 20% of males [43].

Since the earliest studies of OA, generalized involvement of joints was described in postmenopausal females, and...
predominant node formation with early signs of inflammation was observed in the proximal and distal interphalangeal joints of the hands [44]. Nodular hand OA is often associated with a polyarticular and symmetric involvement of major joints such as knees and hips [45]. Erosions may occur in the interphalangeal joints and are characteristic of erosive OA. This disorder tends to occur in middle-aged women, and it is often an acute condition with features of inflammation that subside over a period of months to years, leaving deformed joints and occasional ankylosis [46]. Lower levels of serum E2 and its metabolite 2-hydroxyestronne in urine were recently reported in postmenopausal women who developed radiographically defined knee OA [47].

Failure of estrogen production at menopause is associated with a relevant loss of muscle mass and, therefore, significant impairment of muscle performance and functional capacity [48]. Diminished strength of the quadriceps in women but not men predict knee OA [49], and peri- and postmenopausal women also seem to have less lean body mass when compared with pre-menopausal women [50]. In addition, varus-valgus laxity has more frequently been described in women than in men [51].

The effect of estrogen deficiency on the association between osteoarthritis and osteoporosis
At this time, a complex and paradoxical relationship seems to exist between OA and OP, although there is increasing evidence supporting a close biomechanical and mechanical association between subchondral bone and cartilage [52]. Indeed, microarray profiles have identified a number of genes differentially expressed in OA bone that are key players in the structure and function of both bone and cartilage, including genes that participate in the Wingless-type mouse mammary tumor virus/β-catenin (Wnt/β-catenin) and transforming growth factor-β/mothers against decapentaplegic (TGF-β/SMAD) signaling pathways and their targets [53]. Wnt5b and other genes involved in osteoclast function are differentially expressed between male and female OA bone [53]. Furthermore, aggrecan production, as well as SOX9, type II collagen and parathyroid hormone-related protein mRNA expression was inhibited in sclerotic but not non-sclerotic osteoblasts (OBs), while expression of matrix metalloproteinases MMP-3 and MMP-13 and osteoblast-specific factor 1 by human OA chondrocytes was augmented in a co-culture system. Thus, sclerotic osteoarthritic subchondral OBs may contribute to cartilage degradation and chondrocyte hypertrophy [54].

Current methodological difficulties in detecting and closely following incipient OA lesions at early stages in humans are a major obstacle to better understanding the relationship between OA and OP. Therefore, animal models provide an alternative to study this relationship. However, some species may not be suitable for such studies since OVX provokes strong subchondral bone remodeling and loss in these animals (for example, rodents), and possibly ensuing indirect cartilage damage. Conversely, there are certain advantages to studying OP in rabbits [32] and, in this context, our group has developed an experimental model in mature rabbits where OP markedly aggravates the severity of OA estimated using the Mankin score (Figure 2). Moreover, the increased cartilage damage is correlated with loss of bone mass, suggesting a direct relationship between OA and OP [31].

Several cross-sectional studies have demonstrated an inverse relationship between OP and OA [55,56], while others produced opposite results [57]. However, some confounding variables such as race, obesity and physical activity could explain the mutually exclusive relationship between OA and OP. Thus, overweight individuals and/or those that undertake excessive physical activity could have a higher risk of developing OA and of having a higher bone mass. This controversial relationship is also witnessed at the regional level. Indeed, severe hip OA has a protective role against the age-related decrease in structural and mechanical properties of cancellous bone in the principal compressive region of the ipsilateral femoral head [58]. In turn, subchondral tibial BMD was correlated with future joint space narrowing and it has been proposed as a predictor of knee OA progression [59]. However, other studies have shown a decrease in subchondral BMD associated with knee OA. Indeed, in female patients with relatively mild OA of the knee, a significant decrease in periarticular subchondral BMD was evident, whether or not they had a low spine BMD [60].

Mechanisms underlying the effects of estrogen on joint tissues
Estrogen influences the biology of joint tissues by regulating the activity and expression of key signaling molecules in several distinct pathways (Figure 3).

Canonical estrogen receptor signaling pathway (estrogen response element-dependent)
Estrogen primarily exerts its effects on target tissues by binding to and activating ERs. ERs act as ligand-activated transcription factors in the nucleus that specifically bind to estrogen response elements (EREs) in the promoters of target genes such as the human oxytocin, prolactin, cathepsin D, progesterone receptor, vascular endothelial growth factor, insulin-like growth factor (IGF)-1, or c-fos genes [61], as diagrammatically shown in Figure 3 (pathway 1). The ERE is a 13 base-pair inverted sequence that binds ERs as dimers. Because imperfect palindromic EREs, or even half EREs, are often seen in the regulatory region of estrogen target genes, transcriptional synergism might occur that could include the co-operative recruitment of co-activators, direct interaction between ER dimers, or allosteric modulation of the DNA-ER complexes [62].

ERs contain four functional domains. The variable amino-terminal A/B domainharbors the constitutive activation
function (AF)-1, which modulates transcription in a gene- and cell-specific manner. The central and most conserved C domain contains the DNA binding domain, and it also mediates receptor dimerization. The D domain is a less well understood region. Finally, the carboxy-terminal multifunctional E/F domain holds the ligand-binding domain as well as sites for cofactors, transcriptional activation (AF-2) and nuclear localization (Figure 4) [63]. There are two receptor subtypes, ERα and ERβ, which are different proteins encoded by distinct genes located on chromosomes 6 (q24-q27) and 14 (q21-q22), respectively [64]. These two receptor subtypes have 96% amino acid homology in the DNA binding domain but only 53% identity in the ligand-binding domain. As a result, similar ERE binding properties have been associated with a partially distinct spectrum of ligands for each receptor, although with similar affinities for estrogen. Even weaker amino acid identity is found in the A/B domain of ERα and ERβ (Figure 4). Both receptors also show little conservation in AF-2 and, therefore, several proteins may direct ERα and ERβ to different targets as observed in their contrasting effects at the activator protein (AP)-1 site of the collagenase promoter. Thus, ERα and ERβ have different
transcriptional activities that may contribute to their distinct tissue-specific actions [63,65].

Both ERs are distributed widely throughout the body, displaying distinct but overlapping expression in a variety of tissues. ERα is highly expressed in classical estrogen target tissues such as the uterus, placenta, pituitary and cardiovascular system, whereas ERβ is more abundant in the ventral prostate, urogenital tract, ovarian follicles, lung, and immune system. However, the two ERs are co-expressed in tissues such as the mammary gland, bone, and certain regions of the brain [66]. Although both ER subtypes can be expressed in the same tissue, they may not be expressed in the same cell type. Nonetheless, in cells where the two ER subtypes are co-expressed, ERβ can antagonize ERα-dependent transcription [64]. The generation of human ERα and ERβ mRNA transcripts is a complex process that is controlled by sophisticated regulatory mechanisms leading to the generation of several isoforms/variants for each receptor subtype. Most ERα variants only differ at the 5' untranslated region and they are involved in tissue-specific regulation of ERα gene expression. Several species-specific and common ERβ isoforms have been described, many of which are expressed as proteins in tissues [67].

In articular tissues, both ER types are expressed by the chondrocytes [10], subchondral bone cells [11], synoviocytes [12], ligament fibroblasts [13] and myoblasts [14] in humans and other species. However, ERα is predominant in cortical bone and ERβ predominates in cartilage, cancellous bone and synovium [10,12,68]. More mRNA transcripts for both subtypes of ERs were found in male than in female human cartilage, but there were no differences between different joints, or between cartilage from OA patients and the normal population [10]. In bone, ERα and ERβ are expressed by OBs and they are differentially expressed during rat OB maturation [69]. Pre-osteoclasts express ERα, while osteoclast maturation and bone resorption is associated with the loss of ERα expression [70]. ERβ mRNA and protein are predominantly found in the stroma and lining cells of normal human synovium, independent of sex or menopausal status of the tissue donor [12]. Fibroblasts from human ACL, medial cruciate ligament and patellar tendon express functional ER transcripts. Indeed, 4 to 10% of ACL cells express ERs in patients with acute ACL injuries, approximately twice the proportion found in control subjects [13,71]. In human skeletal muscle, ERα mRNA expression was 180-fold higher than that of ERβ [72]. Remarkably, individuals that undergo high endurance training have more ERα and ERβ mRNA transcripts in skeletal muscles than moderately active individuals [73].

Characterizing the phenotypes of knockout models has advanced our understanding of the role of ER in biological processes. Indeed, ERβ plays a significant role in bone remodeling in female ER knockout mice, whereas ERα does so in both sexes. Thus, male and female ERα−/− mice show decreased bone turnover and greater cancellous bone volume, even though the cortical thickness and BMD was reduced. Female ERβ−/− mice have slightly increased trabecular bone volume, while male animals do not show any change in their bones. Male and female double ER−/− mice
showed significant defects in cortical bone and BMD, while female mice alone displayed a profound decrease in trabecular bone volume [74]. A recent study has shown that ERα−/−β−/− double knockout increased osteophytosis and thinning of the lateral subchondral plate, both osteoarthritic characteristics, in the knee of transgenic mice [75]. These results confirm the relevant changes described in subchondral bone of OVX animal models [27-29]. However, no difference in cartilage damage was observed between the ERα−/−, ERβ−/− and ERα−/−β−/− double knockout and wild-type mice at 6 months of age, although the cartilage damage was very mild in all mice [75]. Whether the absence of significant cartilage damage in all ER knockout mice groups reflects some important differences between ER knockout mice, which lack ER expression since birth, and OVX models that show significant OA cartilage changes associated with estrogen depletion at a later age [7,24-26] remains to be established.

As regards muscle, ERα−/− mice have lower tetanic tension per calculated anatomical cross-sectional and fiber areas in tibialis anterior and gastrocnemius than in wild-type mice. In contrast, ERβ−/− and wild-type mice were comparable in all measures. These results suggest that the effects of estrogen on skeletal muscle are mainly mediated by ERα [76]. With respect to ligaments, no changes in medial cruciate ligament or ACL viscoelastic or tensile mechanical properties were observed in ERβ−/− mice [77].

Non-estrogen response element-mediated genomic ER signaling

The second genomic mechanism involves the interaction of ligand-bound ERs with other transcription factors like Fos/Jun (AP-1-responsive elements), c-Jun/NF-κB and specificity protein 1 (Sp1) recruiting co-regulators to form initiation complexes that regulate the transcription of genes whose promoters do not harbor EREs [64,78]. In this tethering mechanism, ERs do not bind directly to DNA (Figure 3, mechanism 2) and, thus, ERs can up-regulate the expression of promoters containing AP-1 sites, such as the collagenase and IGF-1 genes. Interestingly, E2 exerts distinct transcriptional activation on the AP-1 site of the collagenase promoter depending on whether ERα or ERβ is involved: it elicits transcriptional activation with ERα, while it represses transcription with ERβ [65,78]. The interaction of ERs with Sp1 activates urotoglobin, retinoic acid receptor alpha, IGF-binding protein 4 (IGFBP4), TGF-α, bcl2 and the low-density lipoprotein receptor genes [61,78]. Similarly, suppression of IL-6 expression by E2 occurs through interactions of the ligand bound ER with the NF-κB complex [64].

Ligand-dependent activation of ERs, both ER and non-ERE-mediated, attracts co-regulator molecules that modify the chromatin state, thereby recruiting or hindering the transcriptional complex and representing another level of control in ER gene regulation [61,63,79]. Co-activators stimulate transcription by interacting with helix 12 (H12) of the AF-2 region through their short ‘nuclear receptor boxes’, transducing ligand signals to the basal transcriptional machinery. The best characterized co-activators include the steroid receptor co-activator (SRC) family (SRC1, SRC2 and SRC3) and members of the mammalian mediator complex (thyroid receptor associated proteins, vitamin-D receptor interacting proteins, activator-recruited cofactor) [63,79]. Alternatively, co-repressors that impede transcription include the nuclear receptor co-repressor (NCoR) and the silencing mediator for the retinoic acid and thyroid hormone receptor (SMRT), which interact with ligand-free ER through an elongated amino acid sequence called the CoRNR-box. By contrast, if H12 assumes a ‘charge clamp’ configuration in response to agonist binding, then it could not hold the long NCoR/SMRT helices. Thus, agonist binding reduces the affinity of ERs for co-repressors and increases their affinity for co-activators [63,79]. In addition, both SMRT and NCoR recruit the protein SIN3 and histone deacetylases to form a large co-repressor complex, implicating histone deacetylation in transcriptional repression [79].

In rabbit articular chondrocytes, ERα activation inhibits NF-κB p65 activity and, subsequently, decreases IL-1β-stimulated inducible nitric oxide synthase expression and nitric oxide production [80]. Moreover, ERα and, particularly, ERβ transfection significantly enhances MMP-13 promoter activity through an AP-1 site, which may be modulated through the sites of the Runx-related (Runx) and PEA-3-Ets transcription factors in a rabbit synovial cell line lacking endogenous ER [81]. A normal balance between classic ERE-mediated and non-ERE-mediated ERα, genomic and non-genomic, pathways in cortical bone have also been described in ERα−/− mice and its disruption can lead to an aberrant response to estrogen [82].

Non-genomic ER signaling pathways

Estrogens may also exert their ligand-dependent effects through non-genomic mechanisms that are responsible for more rapid effects, occurring within seconds or minutes of stimulating cell signal transduction pathways, such as the mitogen activated protein (MAP) kinases, in particular the extracellular signal regulated kinase 1/2 (ERK 1/2), p38 and phosphatidylinositol-3 (PI3) kinase/Akt pathways [64]. A small ER population and/or a G-protein-coupled receptor termed GP30, localized at or close to the cell membrane, may elicit these responses [83,84]. ER translocation to the cell membrane is nourished by its interaction with membrane proteins such as caveolin 1/2, striatin and the adaptor proteins Shc and p130 Cas [64]. S-palmitoylation and myristoylation of ERα also promote ERα association with the plasma membrane and its interaction with caveolin-1 [64]. Furthermore, interaction between ER, the tyrosine kinase cSrc and an adaptor protein called modulator of nongenomic action of estrogen receptors (MNAR) generates a signaling complex that may be crucial for the important cSrc activation
and further kinase phosphorylation [85]. Thus, several molecular processes have been shown to mediate the non-genomic effects of ER (Figure 3, pathway 3). However, the precise mechanisms involved in ER localization in the cell membrane, as well as the interaction between ERs and signaling pathways, are yet to be fully established.

There appears to be sexual dimorphism in the non-genomic pathways described in human articular and rat growth plate chondrocytes. Thus, only female cells respond to estrogens by promoting a rapid protein kinase C (PKC)-α-mediated increase in proteoglycan production and alkaline phosphatase activity (PKC increase occurred within 9 minutes and was maximal at 90 minutes). Treatment with the PKC inhibitor chelerythrine blocked these effects [86,87]. PKC activation initiated a signaling cascade involving the ERK1/2 and p38 MAP kinase pathways, which in turn mediated the downstream biological effects of estrogen on alkaline phosphatase activity and [(35)S]-sulfate incorporation in rat growth plate chondrocytes. A membrane receptor has been proposed to elicit this response, although its precise nature remains to be established [88].

Estrogen also regulates intracellular calcium concentrations ([Ca²⁺]i) in a sex-specific and cell maturation state-dependent manner in rat growth plate chondrocytes. Indeed, E₂ more rapidly increased [Ca²⁺]i in resting zone chondrocytes than in growth-zone chondrocytes from female rats, while no effect was observed in chondrocytes from male rats. This effect is mediated by membrane-associated events, phospholipase C-dependent inositol triphosphate-3 production and Ca²⁺ release from the endoplasmic reticulum [89]. In the light of the higher prevalence of OA in postmenopausal females, it has been proposed that these intrinsic sex-specific differences may contribute to OA development [86]. In addition, inclusion of the gender variable when interpreting experimental data and the functional adaptation of donor cells in transplants between organisms of different sexes should be considered [86].

Both ERK phosphorylation kinetics and the duration of phospho-ERK nuclear retention determine the pro- or anti-apoptotic effects of estrogen in bone cells. In fact, E₂-induced transient ERK phosphorylation (lasting 30 minutes) leads to anti-apoptotic effects in OBs and osteocytes, whereas it produces pro-apoptotic signals in osteoclasts through sustained ERK phosphorylation (for at least 24 hours) [90]. Also, the ERK 1/2 and PI3K/Akt/Bad pathways mediate the anti-apoptotic effect of estrogens in C2C12 muscle cells following activation of ERα and ERβ located in diverse cellular compartments such as the mitochondria and perinucleus [91]. Divergent ER-induced gene expression has been found depending on whether the genomic or non-genomic signaling pathways are activated in different cell types. In osteoblastic OB-6 cells, E₂ stimulated complement 3 (C3) and IGF-1 expression after 24 hours, which did not occur following estren administration. This discrepancy is explained by the ERE present in the promoter of the C3 gene and by ER regulating IGF-1 through a protein-protein interaction that influences the AP-1 enhancer. Since estren is a non-genotropic ER activator, it did not activate these ERE- or AP-1-containing genes [92].

**Ligand-independent signaling pathways**

The stimulation of growth factors such as those of the IGF-1, epidermal growth factor, TGF-β/SMAD and Wnt/β-catenin signaling pathways can activate ERs or associated co-regulators via kinase phosphorylation in the absence of ER ligands [64,93-95]. In turn, ERα may also regulate growth factor signaling [64,93-95]. Crosstalk between growth factors and ERs occurs in both the nuclear and cytoplasmic compartments, promoting highly active interactions [64,93-95] (Figure 3, pathway 4).

In OBs, estrogen and TGF-β/SMAD signaling pathways may interact at several levels: activation of the TGF-β pathway by estrogens via TGF-β mRNA induction; increase of estrogen and TGF-β/SMAD signaling due to cytoplasmic MAP kinase activity; direct interaction between ERs and the SMAD proteins in the cytoplasm or nucleus; and interaction between ERs and the TGF-β-inducible early-response gene (TIEG) and Runx-2 transcription factors in the nucleus. Both TIEG and Runx-2 expression are induced by E₂ and TGF-β and, furthermore, TIEG appears to be required for the E₂ and TGF-β-induced regulation of Runx2 expression [95]. Thus, a relevant inhibition of osteoclastic bone resorption by osteocytes occurs as a result of TGF-β enhancement by estrogen [96].

ERs can interact with members of the Wnt/β-catenin signaling system in both the presence and absence of the ligand [97]. Bone response to mechanical forces can be influenced by interactions between the β-catenin and T-cell factor nuclear complex, and ERs in OBs. Indeed, ER modulators suppressed the accumulation of active β-catenin in the nucleus of OBs in vitro within 3 hours following a single period of dynamic strain of magnitude similar to the estimated strain that OBs regularly experience in vivo. Accordingly, microarray analysis performed with RNA extracted from the tibia of ERα-/- mice demonstrated the abrogation of dynamic axial loading-induced expression of Wnt-responsive genes (compared with RNA from the tibia of wild-type mice) [98]. These results suggest that ERα is required for early Wnt/β-catenin-induced bone cell responses to mechanical strain. Indeed, the reduced effectiveness of the bone cell responses to mechanical load associated with estrogen deficiency may alter the bone mass in postmenopausal OP women.

In cynomolgus monkey joint cartilage, IGFBP2-mediated activation of the IGF system induces IGF-1 production, which in turn leads to increased sulfate incorporation into proteoglycans following estrogen administration [99]. In addition,
ERs might interact with the TGF-β and Wnt/β-catenin signaling cascades in articular chondrocytes. Both the Wnt/β-catenin and TGF-β/SMAD signaling pathways play a prominent role in bone and cartilage biology. The TGF-β/SMAD pathway fulfills a beneficial role in bone and cartilage maintenance/repair, although it is also an important protagonist of osteophyte formation [95,100]. In turn, the Wnt/β-catenin system is essential in many biological aspects of bone, from differentiation, proliferation and cellular apoptosis to bone mass regulation and its ability to respond to mechanical load [101]. Activation of the Wnt/β-catenin pathway has also been implicated in OA cartilage damage, and Wnt inhibitors such as the secreted frizzled related protein 3 and Dickkopf-1 might modulate the susceptibility to, and the progress of, hip OA [102].

Although our understanding of the different molecular mechanisms by which estrogen deficits could act on articular tissues and their contribution to OA development has advanced significantly in recent years, it is still limited and more research will be necessary to identify therapeutic targets for this very prevalent disease.

The effects of estrogen replacement therapy and selective estrogen receptor modulators on articular tissues

ERT has displayed mixed effects on joint tissues in various animal and human studies while SERMs conversely have demonstrated a homogeneous response in these tissues (a general description of the effects of SERMs on different tissues is presented in Table 1).

In vivo studies

Estrogen administration in OVX animals has paradoxical effects on joint cartilage, in contrast to the clear benefits of SERM administration [24]. While intra-articular E2 injections [103] and high supraphysiologic estrogen concentrations [104] caused deleterious effects on joint cartilage in a dose- and time-dependent fashion, the beneficial effects of long-term estrogen treatment have been seen in different models [24,25,99]. Early estrogen administration maximizes its positive effects on cartilage [16] and, in turn, tamoxifen decreases cartilage damage in a rabbit model of OA, even in males [105]. Furthermore, tamoxifen antagonized the chondro-destructive effects of high dose intra-articular E2 during early knee OA in rabbits [106]. Also, NNC 45-0781 and levormeloxifen both inhibited the OVX-induced acceleration of cartilage and bone turnover, and they significantly suppressed cartilage damage in female Sprague-Dawley rats [24,107].

In subchondral bone, the effects of long-term ERT have only recently begun to be studied. ERT limits bone formation in both subchondral bone and ephysseal/metaphyseal cancellous bone of the proximal tibia in OVX cynomolgus monkeys [27]. ERT also reduces the prevalence of marginal osteophytes, particularly in the lateral tibial plateau, while the presence of axial osteophytes is not affected. However, neither the cross-sectional area in osteophytes nor its static and dynamic histomorphometric parameters are significantly influenced by ERT [28,108]. In addition, a significant effect of ERT has been described on several components of the IGF system in the synovial fluid of OVX female adult cynomolgus monkeys, suggesting a potential stimulatory effect of estrogen on joint tissues in vivo [109]. In turn, estrogen administration reversed OVX-induced contractile muscle and myosin dysfunction, as well as the OVX-induced increase of muscle wet mass in mature female mice caused by fluid accumulation [110].

Clinical studies

The effect of ERT on the risk of developing OA and on its progression in postmenopausal women remains unclear. Unlike observational clinical studies, some radiographic studies have suggested a protective effect of ERT on the radiographic detection of OA or its progression [111-115]. In a cross-sectional study, ERT significantly reduced the risk of radiographic hip OA, particularly in long-term users [111]. Similarly, an initial cross-sectional analysis of two of the largest studies found an inverse association between ERT use and radiological knee OA, suggesting that ERT may have a chondroprotective effect. However, a subsequent follow-up analysis failed to show significant ERT protection against either the development or progression of radiographic knee OA [112-115]. Additionally, contradictory results were described regarding the association between ERT and the requirement for arthroplasty [116]. Nevertheless, in the largest study, females that received estrogen alone had significantly fewer arthroplasties, particularly in the hip. Thus, unopposed estrogen administration might have a protective effect against the risk of joint replacement, an effect that may be particularly relevant in hip compared to knee OA [117].

Magnetic resonance imaging-estimated subchondral bone attrition and bone-marrow abnormalities associated with cartilage degradation in knee OA was delayed or prevented by ERT or alendronate in postmenopausal women [118]. In turn, ERT may preserve muscle performance. A 12-month trial showed that ERT protects against the detrimental effects of estrogen deficiency on skeletal muscle in early postmenopausal women, thereby positively influencing muscle performance and structure. Moreover, high-impact physical training provided additional benefits [119].

Development of novel estrogen ligands

Recently, novel ER ligands, both pathway-selective and ERβ-selective, have been developed due to the potent anti-inflammatory activity they have been attributed [120,121] (Table 1). Indeed, the pathway-selective ER ligands WAY-169916 and WAY-204688 inhibit NF-κB transcriptional activity in the absence of conventional estrogenic activity in different animal models of inflammatory diseases [122,123].
The suppressive effects of estrogen on inflammatory mediators, including NF-κB, inducible nitric oxide synthase, cyclooxygenase-2, and reactive oxygen species in articular chondrocytes [17,18,80], in association with other selective estrogenic benefits on joint tissues might reflect their potential utility in OA treatment.

Conclusion

Progressive structural and functional changes on articular structures commence at early menopause and persist post-menopause, leading to an increase in the prevalence of OA in the latter population and representing a big impact on health costs worldwide. Both experimental and observational evidence support a relevant role for estrogens in the homeostasis of joint tissues and, hence, in the health status of joints. Indeed, estrogens influence their metabolism at many crucial levels and through several complex molecular mechanisms. These effects of estrogens at joints are either significantly dampened or lost as a result of postmenopausal ovary insufficiency.

A better understanding of the role that estrogen and its deficiency plays in the molecular mechanisms of menopause-induced osteoarthritic changes that affect the different joint structures will help further development of new and precise therapeutic strategies to prevent and/or restore damaged articular tissues in OA. These improved therapeutic approaches must be devoid of the widely known undesirable effects of estrogens in other target tissues. Thus, in OA, which represents a particularly challenging disease due to its effects upon different joint structures, these therapeutic options should target the joint as a whole organ rather than focusing only on cartilage damage.

Competing interests

The authors declare that they have no competing interests.
Acknowledgments

The authors would like to thank Dr Mark Sefton for his assistance in editing the manuscript, and Dr Lenny A Mendoza Torres for her help in preparing the figures. Gabriel Herrero-Beaumont was supported by the SAP2006-02704 research grant from the Spanish Science and Education Ministry, 2006-2008.

References

1. Brandt KD, Radin EL, Dieppe PA, van de Putte L: Yet more evidence that osteoarthritis is not a cartilage disease. Ann Rheum Dis 2005, 64:1261-1264.
2. Sellam J, Herrero-Beaumont G, Berenbaum F: Osteoarthritis: pathogenesis, clinical aspects and diagnosis. In EULAR Compendium on Rheumatic Diseases. Edited by Hans Bijlsma. London, UK: BMJ Publishing Group Ltd; 2009:444-462.
3. Brandt KD, Dieppe P, Radin EL: Etiopathogenesis of osteoarthritis. Rheum Dis Clin North Am 2008, 34:531-559.
4. Herrero-Beaumont G, Roman-Blas JA, Castañeda S, Jimenez SA: Effects of estrogen on skeletal myoblast growth. Biophys Res Commun 1998, 251:214-220.
5. Castañeda S, Largo R, Calvo E, Rodríguez-Salvanés F, Herrero-Beaumont G: Osteoporosis increases the severity of cartilage damage in a surgical model of osteoarthritis. J Orthop Res 2008, 26:210-215.
6. Morisset S, Patry C, Lora M, de Brum-Fernandes AJ: Regulation of cyclooxygenase-2 expression in bovine chondrocytes by culture with interleukin 1β, tumor necrosis factor-α, glucocorticoids, and 17β-estradiol. J Rheumatol 1998, 25:1146-1153.
7. Claassen H, Schünke M, Kurz B: Estradiol protects cultured articular chondrocytes from oxygen-radical-induced damage. Cell Tissue Res 2005, 319:439-445.
8. Scratchan PE Jr, McMaster JH, Diamond PE: Hormone suppression of DNA synthesis in cultured hormone-suppressed DNA synthesis in cultured chondrocyte and osteosarcoma cell line. Clin Orthop Relat Res 1975, 112:340-346.
9. Mackintosh D, Mason RM: Pharmacological actions of 17 beta-oestradiol on articular cartilage chondrocytes and chondrosarcoma chondrocytes in the absence of oestrogen receptors. Biochim Biophys Acta 1988, 962:295-302.
10. Talwar RM, Wong BS, Svoboda K, Harper RP: Effects of estrogen on chondrocyte proliferation and collagen synthesis in skeletally mature articular cartilage. J Oral Maxillofac Surg 2006, 64:600-609.
11. Scheppe AM, Vanderspank L, Rappaport R, Duval-Beaupère G, Corvol M: Age-dependent responsiveness of rabbit and human cartilage cells to sex steroids in vitro. J Steroid Biochem Mol Biol 1991, 40:711-716.
12. Dayani N, Corvol MT, Robel P, Eychenne B, Moncharmont B, Tsagris L, Rappaport R: Estrogen receptors in cultured rabbit articular chondrocytes: influence of age. J Steroid Biochem 1988, 31:351-356.
13. Abe J, Kriketos AD, Roodhope GR, Brown J, Cooper C: Influence of oestrogen on the expression of matrix metalloproteinase-1 in primary cultured human chondrocytes. J Cell Physiol 2004, 200:443-450.
14. Kleinberg DL, Badger TR, Ahmad T, Suda T: Effects of estradiol in the absence of oestrogen receptors on articular chondrocytes. J Endocrinol 1991, 130:33-40.
15. Dayani N, Corvol MT, Robel P, Eychenne B, Moncharmont B, Tsagris L, Rappaport R: Estrogen receptors in cultured rabbit articular chondrocytes: influence of age. J Steroid Biochem 1988, 31:351-356.
16. Heegaard-Andersen P, Tankö LB, Andersen TL, Lundberg CV, Mo JA, Heegaard AM, Delaissé JM, Christgau S: Osteoarthritis as a model of osteonecrosis: a systematic approach. J Bone Miner Metab 2006, 24:195-199.
17. Liang MH, Pillemer SR, Steen VD, Wolfe F: Osteoarthritis. A meta-analysis of sex differences prevalence, incidence and severity. Osteoarthritis Cartilage 2003, 11:469-477.
18. Doherty M, Lunt M: Osteoarthritis in women. Rheum Dis Clin North Am 2008, 34:531-559.
19. Scheppe AM, Vanderspank L, Rappaport R, Duval-Beaupère G, Corvol M: Age-dependent responsiveness of rabbit and human cartilage cells to sex steroids in vitro. J Steroid Biochem Mol Biol 1991, 40:711-716.
20. Heegaard-Andersen P, Tankö LB, Andersen TL, Lundberg CV, Mo JA, Heegaard AM, Delaissé JM, Christgau S: Osteoarthritis as a model of osteonecrosis: a systematic approach. J Bone Miner Metab 2006, 24:195-199.
21. Liang MH, Pillemer SR, Steen VD, Wolfe F: Osteoarthritis. A meta-analysis of sex differences prevalence, incidence and severity. Osteoarthritis Cartilage 2003, 11:469-477.
22. Doherty M, Lunt M: Osteoarthritis in women. Rheum Dis Clin North Am 2008, 34:531-559.
23. Johnell O, Prince RL, Dieppe P, Black DM, Johnson CC, Bierma-Zeinstra SM, van Leeuwen JP, Bierma-Zeinstra SM, van Leeuwen JP, Bierma-Zeinstra SM, van Leeuwen JP: The impact of knee and hip osteoarthritis on societal costs and on the patient’s ability to work: a systematic review. Ann Rheum Dis 2009, 68:1146-1153.
24. Johnell O, Prince RL, Dieppe P, Black DM, Johnson CC, Bierma-Zeinstra SM, van Leeuwen JP, Bierma-Zeinstra SM, van Leeuwen JP: The impact of knee and hip osteoarthritis on societal costs and on the patient’s ability to work: a systematic review. Ann Rheum Dis 2009, 68:1146-1153.
25. Johnell O, Prince RL, Dieppe P, Black DM, Johnson CC, Bierma-Zeinstra SM, van Leeuwen JP, Bierma-Zeinstra SM, van Leeuwen JP: The impact of knee and hip osteoarthritis on societal costs and on the patient’s ability to work: a systematic review. Ann Rheum Dis 2009, 68:1146-1153.
Park HJ, Yoon SH, Kim BS, Yim SV, Park HK, Chung JH: Estrogen receptor-alpha gene haplotype is associated with primary knee osteoarthritis in Korean population. Arthritis Res Ther 2003, 5:821-828.

39. Loughlin J, Sinhaiser JS, Mustafa Z, Carr AJ, Clapham K, Bloomfield VA, Chitnavis J, Bailey A, Sykes B, Chapman K: Association analysis of the vitamin D receptor gene, the type I collagen gene COL1A1, and the estrogen receptor gene in hereditary osteoarthritis. J Rheumatol 1997, 24:779-784.

40. Lian K, Li L, Zmuda JM, Nevitt MC, Hochberg MC, Lee JM, Li, Jane NE: Estrogen receptor alpha genotype is associated with a reduced prevalence of radiographic hip osteoarthritis in elderly Caucasian women. Osteoarthritis Cartilage 2007, 15: 1161-1165.

41. Felson DT, Zhang Y, Hannan MT, Naimark A, Weissman BN, Aliabadi P, Levy D: The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum 1995, 38:1500-1505.

42. Yamada P: Osteoarthritis and the rheumatic diseases. In Population Studies of the Rheumatic Diseases. Volume IV. Edited by Bennett PH, Wood PH. Amsterdam: Excerpta Medica; 1982:26-37.

43. Nadkar MY, Samant RS, Vaidya SS, Borges NE: Relationship between osteoarthritis of knee and menopause. J Assoc Phys Ind 1997, 49:1161-1163.

44. Kelley RH, Moore R: Generalized osteoarthritis and Heberden nodes. BMJ 1952, 1:181-187.

45. Felson DT, Nevitt MC: The effects of estrogen on osteoarthritis. Curr Opin Rheumatol 1998, 10:269-272.

46. Punzi L, Remonda R, Sfriso P: Erosive osteoarthritis. Best Pract Res Rheumatol 2004, 18:739-758.

47. Sowers MR, McConnell D, Jannausch M, Buyuktur AG, Hochberg MC, Lee JM, Li J, Park HJ, Yoon SH, Kim BS, Yim SV, Park HK, Chung JH: Periarticular osteoporosis in osteoarthritis of the knee. J Rheumatol 1998, 25:2187-2194.

48. Klingen CM: Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001, 29:2905-2919.

49. Gruber CJ, Gruber DM, Gruber IM, Wieser F, Huber JC: Anatomy of the estrogen response element. Trends Endocrinol Metab 2004, 15:73-78.

50. Ellmann S, Stich H, Thiel F, Beckmann MW, Strick R, Strissel PL: Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci 2009, 66:2405-2426.

51. Shin boilers B, Greger JG, Nagpal S, Freedman LP: Signaling by estrogens. J Cell Physiol 2007, 213:610-617.

52. Wewa H, Andersson S, Cheng G, Simpson ER, Warner M, Gustafson JA: Update on estrogen signaling. FEBS Lett 2003, 546:17-24.

53. Jhiang S, Gustafsson JA: Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interact 2003, 3: 281-292.

54. Hirata S, Shoda T, Kato J, Hoshi K: Isoform/variant mRNAs for sex steroid hormone receptors in humans. Trends Endocrinol Metab 2003, 14:124-128.

55. Beaudoin R, Sipilä J, Seidel L, Ethgen O, Henrotin Y, Reginster JY: Bone mineral density predicts future joint space narrowing at the medial femoral-tibial compartment in patients with knee osteoarthritis. Bone 2003, 32:541-545.

56. Karvon EN, Miller PR, Nelson DA, Granda JL, Fernandez-Madrid F: Periarticular osteoporosis in osteoarthritis of the knee. J Rheumatol 1998, 25:2187-2194.

57. Klingen CM: Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001, 29:2905-2919.

58. Gruber CJ, Gruber DM, Gruber IM, Wieser F, Huber JC: Anatomy of the estrogen response element. Trends Endocrinol Metab 2004, 15:73-78.

59. Ellmann S, Stich H, Thiel F, Beckmann MW, Strick R, Strissel PL: Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci 2009, 66:2405-2426.

60. Sipilä S, Poutamo J: Erosive osteoarthritis. Best Pract Res Rheumatol 2004, 18:739-758.

61. Sowers MR, McConnell D, Jannausch M, Buyuktur AG, Hochberg MC, Jamadar DA: Estriol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum 2006, 54:2481-2487.

62. Sipilä S: Body composition and muscle performance during menopause and hormone replacement therapy. J Endocrinol Invest 2003, 26:893-901.

63. Imamura F, Shankar KD, Brandt KD, Katz BP, Mazzuca SA, Braunstein EM, Byrd D: Reduced quadriceps strength relative to body weight: a risk factor for knee osteoarthritis in women? Arthritis Rheum 1998, 41:1951-1959.

64. Sipilä S, Poutamo J: Muscle performance, sex hormones and training in peri-menopausal and post-menopausal women. Scand J Med Sci Sports 2005, 13:19-25.

65. Sharma L, Lou C, Felson DT, Dunlop DD, Kirwan-Mellis G, Hayes Kw, Weinrich D, Buchanan TS: Laxity in healthy and osteoarthritic knees. Arthritis Rheum 1999, 42:861-870.

66. Sipilä S, Poutamo J: Muscle performance, sex hormones and training in peri-menopausal and post-menopausal women. Scand J Med Sci Sports 2005, 13:19-25.

67. Hopwood B, Tykyn A, Findlay DM, Fazzalari NL: Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling. Arthritis Res Ther 2007, 9:R100.

68. Sanchez C, Deberg MA, Piccardi N, Msika P, Regnier JY, Henrotin YE: Bone osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1beta and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthritis Cartilage 2005, 13:979-987.

69. Stewart A, Black A: Bone mineral density in osteoarthritis. Curr Opin Rheumatol 2000, 12:464-467.

70. Dequeker J, Aerssens J, Luyten FP: Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship. Clin Exp Rheumatol 2003, 21:459-467.

71. Ng MC, Revell PA, Beer M, Boucher BJ, Cohen RD, Currey LF: Incidence of metabolic bone disease in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1984, 43:370-377.

72. Pentl E, Baleani M, Ohman C, Barrett F, Vicent M: Structural parameters and mechanical strength of cancellous bone in the femoral head in osteoarthritis do not depend on age. Bone 2007, 41:760-768.

73. Bruyere O, Dardenne C, Lejeune E, Zegels B, Pahaut A, Richy F, Seidel L, Ethgen O, Henrotin Y, Regnier JY: Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoral-tibial compartment in patients with knee osteoarthritis. Bone 2003, 32:541-545.

74. Karvon EN, Miller PR, Nelson DA, Granda JL, Fernandez-Madrid F: Periarticular osteoporosis in osteoarthritis of the knee. J Rheumatol 1998, 25:2187-2194.
receptor beta enhances MMP-13 promoter activity in HIG-82 cells and that this enhancement can be influenced by ligands and involves specific promoter sites. Biochem Cell Biol 2007, 85:328-336.

82. Syed FA, Mödder UI, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL, Kholas S: Skeletal effects of estrogen are mediated by opposing actions of classical and non-classical estrogen receptor pathways. J Bone Miner Res 2005, 20:1992-2001.

83. Levin ER: Cellular functions of plasma membrane estrogen receptors. Steroids 2002, 67:471-475.

84. Revankar CM, Cimino DF, Sklar LA, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates estrogen signaling. Science 2005, 307:1625-1630.

85. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskski BJ: Estrogen receptor interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 2002, 99:14783-14788.

86. Heino TJ, Hentunen TA, Valkonen HK, Boyan BD: Human articular chondrocytes exhibit sexual dimorphism in their responses to 17b-estradiol. Osteoarthris Cartilage 2005, 13: 330-337.

87. Boyan BD, Schwartz Z: Rapid vitamin D-dependent PKC signaling shares features with estrogen-dependent PKC signaling in cartilage and bone. Steroids 2004, 69:591-597.

88. McMillan J, Fatehi-Sedeh S, Sylvia VL, Bingham V, Zhong M, Boyan BD, Schwartz Z: Sex-specific regulation of growth plate chondrocytes by estrogen is via multiple MAP kinase signal-transduction pathways. Biochem Biophys Acta 2006, 1763:381-392.

89. Eckenstein Ekstein J, Nasatzky E, Boyan BD, Ornoy A, Schwartz Z: Growth-plate chondrocytes respond to 17beta-estradiol with sex-specific increases in IP3 and intracellular calcium ion signaling via a capacitative entry mechanism. Steroids 2005, 70: 775-786.

90. Chen JR, Plotkin LI, Aguirre JJ, Han L, Ilka RL, Kousteni S, Bellido T, Manolagas SC: Transient versus sustained phosphorylation and nuclear accumulation of ERKs under anti-estrogenic and anti-apoptotic effects of estrogens. J Biol Chem 2005, 280:4632-4638.

91. Boland R, Vasconsuelo A, Milanesi L, Ronda AC, de Boland AR: 17beta-Estradiol signaling in skeletal muscle cells and its relationship to apoptosis. Steroids 2008, 73:859-863.

92. Heino TJ, Hentunen TA, Valkonen HK, Boyan BD: Classical estrogen receptor pathways. J Cell Biochem 2008, 103:383-392.

93. Boland R, Vasconsuelo A, Milanesi L, Ronda AC, de Boland AR: 17beta-Estradiol signaling in skeletal muscle cells and its relationship to apoptosis. Steroids 2008, 73:859-863.

94. Fagan DH, Yee D: Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:423-429.

95. Dawe JR, Subramaniam M, Ingle JM, Oursler MJ, Rajamannan NM, Spelsberg TC: Estrogen-TGFbeta cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors. J Cell Biochem 2008, 103:383-392.

96. Dixon TJ, Hentunen TA, Valkonen HK: Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: enhancement by estrogen. J Cell Biochem 2002, 85: 185-197.

97. Kozumppiko AP, Takayama K, Ito S, Furutani T, Sawatsubashi S, Maki A, Suzuki E, Kawasaki Y, Akiyama T, Tabata T, Kato S: Wnt/beta-catenin and estrogen receptor confluence in vivo. J Biol Chem 2004, 279:40255-40258.

98. Armstrong VJ, Muzylak M, Sunters A, Zaman G, Saxon LK, Price JS, Lanyon LE: Wnt/beta-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor alpha. J Biol Chem 2007, 282: 20715-20727.

99. Richmond RS, Carlson CS, Register TC, Shanker G, Loeser RF: Functional estrogen receptors in adult cartilaginous. Estrogen replacement therapy increases chondrocyte synthesis of proteoglycans and insulin-like growth factor binding protein 2. Arthritis Rheum 2000, 43:2081-2090.

100. Blenley Davidson EN, van der Kraan PM, van den Berg WB: TGF-beta and osteoarthritis. Osteoarthritis Cartilage 2007, 15:597-604.

101. Johnson ML, Kamel MA: The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 2007, 19:376-382.

102. Bocci M: Wnt-beta catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol 2008, 4:550-556.

103. Tsai CL, Liu TK: Estradiol-induced knee osteoarthritis in ovariecetomized rabbits. Clin Orthop Rel Res 1993, 291:305-302.

104. Eng MC, Harper RP, Le CT, Wong BS: Effects of estrogen on the condylar cartilage of the rat mandible in organ culture. J Oral Maxillofac Surg 1999, 57:818-823.

105. Rosner IA, Boja BA, Goldberg VM, Moskowitz RW: Tamoxifen therapy in experimental osteoarthritis. Curr Ther Res 1983, 34: 644-648.

106. Tsai CL, Liu TK: Inhibition of estradiol-induced early osteoarthritic changes by tamoxifen. Life Sci 1992, 50:1943-1951.

107. Christgau S, Tanko LB, Cloos PA, Mournitzen U, Christiansen C, Delaisse JM, Hegge-Andersen P: Suppression of elevated cartilage turnover in postmenopausal women and in ovariecetomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 2004, 11:508-518.

108. Olson EJ, Lindgren BR, Carlson CS: Effects of long-term estrogen replacement therapy on bone turnover in peritellar tibial osteocytes in surgically postmenopausal cynomolgus monkeys. Bone 2008, 42:907-913.

109. Fernhoff JK, Richmond RS, Carlson CS, Cherpes T, Holly JM, Loeser RF: Estrogen replacement therapy modulation of the insulin-like growth factor system, in monkey knee joints. Arthritis Rheum 1999, 42:2103-2111.

110. Moran AL, Nelson SA, Landisch RM, Warren GL, Lowe DA: Estradiol replacement reverses ovariectomy-induced muscle contracture and myosin dysfunction in mature female mice. J Appl Physiol 2007, 102:1387-1393.

111. Nevitt MC, Cummings SR, Lane NE, Hochberg MC, Scott JC, Pressman AR, Genant HK, Cauley JA: Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1996, 156:2073-2080.

112. Spector TD, Nandra D, Hart DJ, Doyle DV: Is hormone replacement therapy protective for hand and knee osteoarthritis in women? The Chingford Study. Ann Rheum Dis 1997, 56:432-436.

113. Hart DJ, Doyle DV, Spector TD: Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study. Arthritis Rheum 1999, 42:17-24.

114. Hannan MT, Felson DT, Anderson JJ, Namark A, Kannel WB: Estrogen use and radiographic osteoarthritis of the knee in women: the Framingham Osteoarthritis Study. Arthritis Rheum 1990, 33:525-532.

115. Zhang Y, McClendon TE, Hannan MT, Chaisson CE, Klein R, Wilson PW, Felson DT: Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framing ham Study. Arthritis Rheum 1998, 41:1867-1873.

116. de Klerk BM, Schiphol D, Groeneveld FP, Koes BW, van Osch GJ, van Meurs JB, Biema-Zeinstra SM: Limited evidence for a protective effect of unopposed estrogen therapy for osteoarthritis of the hip: a systematic review. Rheumatology 2009, 48:104-112.

117. Cirillo DJ, Wallace RB, Wu L, Yoo RA: Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative. Arthritis Rheum 2006, 54:3184-3204.

118. Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, Peterfy C, Visser M, Harris WB, Kritchevsky SB, Peterfy C, Visser M, Harris WB, Kritchevsky SB, Health, Aging and Body Composition Study: The relationship of antiresorptive drug use to structural findings and symptoms in the Women’s Health Initiative. Arthritis Rheum 2004, 50:3518-3525.

119. Taaffe DR, Sipilä S, Cheng S, Puolakka J, Toivainen J, Suominen H: The effect of hormone replacement therapy and/or exercise on skeletal muscle attenuation in postmenopausal women: a yearlong intervention. Clin Physiol Funct Imaging 2005, 25:297-304.

120. Harnish DC: Estrogen receptor ligands in the control of pathogenic inflammation. Curr Opin Investig Drugs 2008, 9:797-1001.

121. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB: Selective

Available online http://arthritis-research.com/content/11/5/241

(page number not for citation purposes)
estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008, 63:163-181.
122. Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewahaw RE, Miller CP, Kharode YP, Mazolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC Jr: Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 2003, 144:4241-4249.
123. Keith JC Jr, Albert LM, Leathurby Y, Follettie M, Wang L, Borges-Marcucci L, Chadwick CC, Steffan RJ, Harnish DC: The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R427-438.